Sutimlimab FDA Approval Status
Last updated by Judith Stewart, BPharm on May 19, 2020.
FDA Approved: No
Generic name: sutimlimab
Treatment for: Cold Agglutinin Disease (CAD)
Sutimlimab is a first-in-class selective inhibitor of complement C1s in development for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD).
Development Timeline for sutimlimab
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.